Practice areas

Capital markets; Corporate & commercial; Private equity, venture capital & funds; Dispute resolution

Introduction

Ma Yunyan graduated from the Law Department of Peking University in 1984. She joined Shu Jin Law Firm in 1994, specialising in mergers and acquisitions, securities issuance in the capital markets, etc. She was employed as a member of the Listing Committee of the Shenzhen Stock Exchange, a member of the first and second GEM Issuance Review Committees of the China Securities Regulatory Commission. She is currently a member of the first Municipal Committee of the Shenzhen Stock Exchange under the registration system, and an arbitrator of the Shenzhen Court of International Arbitration.

Ma has been practicing law for more than 20 years, focusing on the capital market business, and has extensive experience in issuing stocks and bonds and mergers and acquisitions at home and abroad. She has been well-received by clients and has been rated as one of China’s outstanding lawyers by well-known international and domestic rating agencies many times. Some representative projects Ma handled include: Wisesoft, Das Intellitech, SUNWODA, Hybribio Biotech, Frd Science & Technology, CIMC Vehicles, Kawin Technology, Mehow and other IPOs and listing of A-shares.

Ma also managed the IPO of Aac Technologies on the main board of the Hong Kong Stock Exchange (HKEX). Vanke’s B-to-H share listing on the main board of HKEX; Ningbo Shanshan shares spin-off of Fy Financial and FIRS to the HKEX H-share listing project, CIMC Group spin-off of CIMC Vehicle to the HKEX H-share listing project, and Huaxin Cement B shares to H shares project. Among them, Huaxin Cement’s B-to-H share project was rated as the 15th Most Creative Project of New Fortune .

Ma also invested in Silkroad Visual on behalf of the China Culture Industry Fund; and participated in the restructuring of BGI’s infection prevention and control business sector on behalf of Songhe International Capital. Ma assisted the listed company Boya-Bio to introduce China Resources Pharmaceutical as a controlling stakeholder. This project, as well as the domestic listing of CIMC Vehicle, were both awarded the 15th Most Creative Project of New Fortune, and recognsied in Deals of the Year 2021 by China Business Law Journal.

Back to China A-List 2022